X

Drug Profile

Research programme: polycystic kidney disorder therapies - Healx/PKD Charity

Latest Information Update: 08 Mar 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Healx
Developer Healx; PKD Charity
Class Urologics
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Research Autosomal dominant polycystic kidney disease; Autosomal recessive polycystic kidney disease

Most Recent Events

03 Mar 2021 Healx and the PKD Charity agree to co-develop therapeutics for polycystic kidney diseases
03 Mar 2021 Early research in Autosomal dominant polycystic kidney disease in United Kingdom
03 Mar 2021 Early research in Autosomal recessive polycystic kidney disease in United Kingdom

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com